Paediatric Active Enhanced Disease Surveillance (PAEDS) annual report 2016: Prospective hospital-based surveillance for serious paediatric conditions
DOI:
https://doi.org/10.33321/cdi.2019.43.5Keywords:
paediatric, surveillance, hospital, vaccine preventable diseases, adverse event following immunisation, acute flaccid paralysis, encephalitis, influenza, intussusception, pertussis, varicella zoster virus, meningococcal, group A streptococcusAbstract
Introduction
The Paediatric Active Enhanced Disease Surveillance (PAEDS) network is a hospital-based active surveillance system employing prospective case ascertainment for selected serious childhood conditions, particularly vaccine preventable diseases and potential adverse events following immunisation (AEFI). PAEDS data is used to better understand these conditions, inform policy and practice under the National Immunisation Program, and enable rapid public health responses for certain conditions of public health importance. PAEDS enhances data available from other Australian surveillance systems by providing prospective, detailed clinical and laboratory information on children with selected conditions. This is the third annual PAEDS report, and presents surveillance data for 2016.
Methods
Specialist nurses screened hospital admissions, emergency department records, laboratory and other data, on a daily basis in 5 paediatric tertiary referral hospitals in New South Wales, Victoria, South Australia, Western Australia and Queensland to identify children with the conditions under surveillance. Retrospective data on some conditions was also captured by an additional hospital in the Northern Territory. Standardised protocols and case definitions were used across all sites. Conditions under surveillance in 2016 included acute flaccid paralysis (AFP) (a syndrome associated with poliovirus infection), acute childhood encephalitis (ACE), influenza, intussusception (IS; a potential AEFI with rotavirus vaccines), pertussis, varicella-zoster virus infection (varicella and herpes zoster), invasive meningococcal and invasive Group A streptococcus diseases. Most protocols restrict eligibility to hospitalisations; Emergency Department (ED) only presentations are also included for some conditions.
Results
In 2016, there were 673 cases identified across all conditions under surveillance. Key outcomes of PAEDS included: contribution to national AFP surveillance to reach World Health Organization (WHO) reporting targets; identification of the leading infectious causes of acute encephalitis which included human parechovirus, influenza, enteroviruses, Mycoplasma pneumoniae, and bacterial meningo-encephalitis; demonstration of high influenza activity with vaccine effectiveness (VE) analysis demonstrating some protection offered through vaccination. All IS cases associated with vaccine receipt were reported to the relevant state health department. Varicella and herpes zoster case numbers increased from previous years associated with suboptimal vaccination in up to 40% of cases identified. Pertussis surveillance continued in 2016 with the addition of test negative controls captured for estimating vaccine effectiveness. Surveillance for invasive meningococcal disease showed predominance for serotype B in absence of immunisation, and new invasive group A streptococcus surveillance captured severe disease in children.
Conclusions
PAEDS continues to provide unique policy-relevant data on serious paediatric conditions using hospital-based sentinel surveillance.
Downloads
References
McRae J, Quinn HE, Macartney K. Paediatric Active Enhanced Disease Surveillance (PAEDS) annual report 2015: Prospective hospital-based surveillance for select vaccine preventable diseases and adverse events following immunisation. Communicable Diseases Intelligence 2017;41(3).
Zurynksi YA, McRae J, Quinn HE, Wood NJ, Macartney K. Paediatric Active Enhanced Disease Surveillance (PAEDS) inaugural report 2014: Prospective hospital-based surveillance for select vaccine preventable diseases and adverse events following immunisation. Communicable Diseases Intelligence 2016;In press.
Zurynski Y, McIntyre P, Booy R, Elliott EJ, on behalf of the PAEDS Investigators Group. Paediatric Active Enhanced Disease Surveillance: a new surveillance system for Australia. Journal of Paediatrics and Child Health 2013;49(7):588-594.
Roberts J, Hobday L, Ibrahim A, Aitken T, Thorley B. Australian National Enterovirus Reference Laboratory annual report, 2014. Commun Dis Intell Q Rep 2017;41(2):E161-e180.
World Health Organization. Global Polio Eradication Initiative, Surveillance. Accessed on 24.10.17. Available from: http://polioeradication.org/who-we-are/strategy/surveillance/
Paediatric Trials Network Australia. WebSpirit. 2013. Accessed on 24 October 2017. Available from: http://www.ptna.com.au/index.php/webspirit
Britton PN, Dale RC, Booy R, Jones CA. Acute encephalitis in children: Progress and priorities from an Australasian perspective. J Paediatr Child Health 2015;51(2):147-158.
Elliott EJ, Zurynski YA, Walls T, Whitehead B, Gilmour R, Booy R. Novel inpatient surveillance in tertiary paediatric hospitals in New South Wales illustrates impact of first-wave pandemic influenza A H1N1 (2009) and informs future health service planning. Journal of Paediatrics and Child Health 2012;48(3):235-241.
Bines JE, Kohl KS, Forster J, Zanardi LR, Davis RL, Hansen J, et al. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004;22(5-6):569-574.
Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011;29(16):3061-3066.
Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia’s National Immunization Program. Clin Infect Dis 2013;57(10):1427-1434.
Quinn HE, Wood NJ, Cannings KL, Dey A, Wang H, Menzies RI, et al. Intussusception after monovalent human rotavirus vaccine in Australia: severity and comparison of using healthcare database records versus case confirmation to assess risk. The Pediatric infectious disease journal 2014;33(9):959-965.
Pillsbury A, Quinn HE, McIntyre PB. Australian vaccine preventable disease epidemiological review series: Pertussis, 2006–2012. Communicable Diseases Intelligence 2014;38(3):E179-194.
Marshall H, Quinn H, Gidding H, Richmond P, Crawford N, Gold N, et al. Severe and complicated varicella in the post-varicella vaccine era and associated genotypes. Presented at: 15th National Immunisation Conference; 7–9 June 2016; Brisbane.
Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports 2005;54(Rr-7):1-21.
Peltola H. Meningococcal disease: still with us. Reviews of infectious diseases 1983;5(1):71-91.
Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS microbiology reviews 2007;31(1):27-36.
Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 2009;123(3):e502-509.
Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Human vaccines 2011;7(4):458-465.
Wang B, Clarke M, Thomas N, Howell S, Afzali HH, Marshall H. The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. The Pediatric infectious disease journal 2014;33(3):316-318.
Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. Journal of the American Medical Association 1993(269):384-389.
Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. Journal of Paediatrics and Child Health. 2007(43):203-213.
Australian Bureau of Statistics (ABS). Population by age and sex, regions of Australia, 2016. (Cat. No. 3235.0). . Canberra: ABS, 2017.
Desai S, Smith T, Thorley BR, Grenier D, Dickson N, Altpeter E, et al. Performance of acute flaccid paralysis surveillance compared with World Health Organization standards. Journal of Paediatrics and Child Health 2015;51(2):209-214.
Britton P, Dale R, Blyth C, Clark J, Crawford N, Marshall HS, et al. The Causes and Clinical Features of Childhood Encephalitis in Australia: A Multicentre, Prospective, Cohort Study. Open Forum Infectious Diseases, 2016;3(Suppl_1,1).
Britton P, Dale R, Clarke J, Crawford N, Marshall H, Elliott E, et al. Emerging epidemic viruses are an important cause of encephalitis in infants and children: findings from Australian cohort (ACE) study (2013-2016). Presented at: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Britton PN, Blyth CC, Macartney K, Dale RC, Li-Kim-Moy J, Khandaker G, et al. The Spectrum and Burden of Influenza-Associated Neurological Disease in Children: Combined Encephalitis and Influenza Sentinel Site Surveillance From Australia, 2013-2015. Clin Infect Dis 2017;65(4):653-660.
Britton PN, Dale RC, Blyth CC, Macartney K, Crawford NW, Marshall H, et al. Influenza-associated Encephalitis/Encephalopathy Identified by the Australian Childhood Encephalitis Study 2013-2015. The Pediatric infectious disease journal 2017;36(11):1021-1026.
Blyth CC, Macartney KK, Hewagama S, Senanayake S, Friedman ND, Simpson G, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2014: the Influenza Complications Alert Network (FluCAN). Eurosurveillance In press.
Australian Government Department of Health. Australian influenza surveillance report 2015;10(Reporting Period 25 September to 9 October 2015).
Australian Technical Advisory Group on Immunisation. ATAGI Bulletin 58th Meeting 15 and 16 October 2015. In: Department of Health: Immunisation Branch, editor. Canberra.
Blyth C. on behalf of the PAEDS and FluCAN Networks. Influenza. Paediatric Active Enhanced Disease Surveillance (PAEDS): 10 Year Anniversary Showcase: ; 2017; Melbourne.
Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011;29(16):3061-3066.
NNDSS Annual Report Working Group. Australia’s notifiable disease status, 2014: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2016;40(1):E48-E145.
Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook. 10th. Canberra: Australian Government Department of Health and Ageing; 2013.
Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014;384(9953):1521-1528.
Quinn HE, Snelling TL, Habig A, Chiu C, Spokes PJ, McIntyre PB. Parental Tdap boosters and infant pertussis: a case-control study. Pediatrics 2014;134(4):713-720.
Quinn H, Gidding H, Marshall H, Booy R, Elliott E, Richmond P, et al. Varicella vaccine effectiveness over 10 years in Australia. (Paper in progress: Planned submission to Journal of infection 2018).
Ching NS, Crawford N, McMinn A, Baker C, Azzopardi K, Brownlee K, et al. Prospective surveillance of paediatric invasive group A streptococcal infection. Journal of the Pediatric Infectious Diseases Society In Press.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2019 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
